Cost-utility analysis of the use of prophylactic mesh augmentation compared with primary fascial suture repair in patients at high risk for incisional hernia

被引:43
|
作者
Fischer, John P. [1 ]
Basta, Marten N. [1 ]
Wink, Jason D. [1 ]
Krishnan, Naveen M. [2 ]
Kovach, Stephen J. [1 ]
机构
[1] Hosp Univ Penn, Div Plast Surg, Perelman Sch Med, Philadelphia, PA 19104 USA
[2] Georgetown Univ Hosp, Dept Plast Surg, Washington, DC 20007 USA
关键词
RANDOMIZED CONTROLLED-TRIAL; ABDOMINAL-WALL CLOSURE; MIDLINE LAPAROTOMY; CLINICAL-TRIAL; SYNTHETIC MESH; UNITED-STATES; HEALTH; PLACEMENT; PREVENTION; METAANALYSIS;
D O I
10.1016/j.surg.2015.02.030
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Although hernia repair with mesh can be successful, prophylactic mesh augmentation (PMA) represents a potentially useful preventative technique to mitigate incisional hernia risk in select high-risk patients. The efficacy, cost-benefit, and societal value of such an intervention are not known. The aim of this study was to determine the cost-utility of using prophylactic mesh to augment fascial incisions. Methods. A decision tree model was employed to evaluate the cost-utility of using PMA relative to primary suture closure (PSC) after elective laparotomy. The authors adopted the societal perspective for cost and utility estimates. A systematic review of the literature on PMA. was performed. The costs in this study included direct hospital costs and indirect costs to society, and utilities were obtained through a survey of 300 English-speaking members of the general public evaluating 14 health state scenarios relating to ventral hernia. Results. PSC without mesh demonstrated an expected average cost of $17,182 (average quality-adjusted life-year [QALY] of 21.17) compared with $15,450 (expected QALY was 21.21) for PMA. PSC was associated with an incremental cost-efficacy ratio (ICER) of -$42,444/QALY compared with PMA such that PMA was more effective and less costly. Monte Carlo sensitivity analysis was performed demonstrating more simulations resulting in ICERs for PSC above the willingness-to-pay threshold of $50,000/QALY, supporting the finding that PMA is superior. Conclusion. Cost-utility analysis of PSC compared to PMA for abdominal laparotomy closure demonstrates PMA to be more effective, less costly, and overall more cost-effective than PSC.
引用
收藏
页码:700 / 711
页数:12
相关论文
共 50 条
  • [31] Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea
    Park, Sun-Kyeong
    Hong, Sung-Hyun
    Kim, HyoJin
    Kim, Sungju
    Lee, Eui-Kyung
    CLINICAL THERAPEUTICS, 2019, 41 (06) : 1066 - 1079
  • [32] Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
    Men, Peng
    Liu, Tianbi
    Zhai, Suodi
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2020, 13 : 2823 - 2831
  • [33] Ventral hernia repair in high-risk patients and contaminated fields using a single mesh: proportional meta-analysis
    Morales-Conde, S.
    Hernandez-Granados, P.
    Tallon-Aguilar, L.
    Verdaguer-Tremolosa, M.
    Lopez-Cano, M.
    HERNIA, 2022, 26 (06) : 1459 - 1471
  • [34] Ventral hernia repair in high-risk patients and contaminated fields using a single mesh: proportional meta-analysis
    S. Morales-Conde
    P. Hernández-Granados
    L. Tallón-Aguilar
    M. Verdaguer-Tremolosa
    M. López-Cano
    Hernia, 2022, 26 : 1459 - 1471
  • [35] Cost-Utility Analysis of Transcatheter Aortic Valve Implantation versus Surgery in High-Risk Severe Aortic Stenosis Patients in Thailand
    Permsuwan, Unchalee
    Yoodee, Voratima
    Buddhari, Wacin
    Wongpraparut, Nattawut
    Thonghong, Tasalak
    Cheewatanakornkul, Sirichai
    Meemook, Krissada
    Sakiyalak, Pranya
    Duangpakdee, Pongsanae
    Yadee, Jirawit
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2022, 14 : 487 - 498
  • [36] Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand
    Thanaporn Bussabawalai
    Kittiphong Thiboonboon
    Yot Teerawattananon
    Cost Effectiveness and Resource Allocation, 17
  • [37] Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand
    Bussabawalai, Thanaporn
    Thiboonboon, Kittiphong
    Teerawattananon, Yot
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2019, 17 (1)
  • [38] Cost-Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand
    Deerochanawong, Chaicharn
    Vareesangthip, Kriengsak
    Piyayotai, Dilok
    Thongsuk, Dittaya
    Pojchaijongdee, Nuch
    Permsuwan, Unchalee
    DIABETES THERAPY, 2021, 12 (07) : 1947 - 1963
  • [39] Comment to: Ventral hernia repair in high-risk patients and contaminated fields using a single mesh: proportional meta-analysis
    Li, Junsheng
    Ji, Zhenling
    HERNIA, 2024, 28 (05) : 2021 - 2022
  • [40] Correction: Ventral hernia repair in high-risk patients and contaminated fields using a single mesh: proportional meta-analysis
    S. Morales-Conde
    P. Hernández-Granados
    L. Tallón-Aguilar
    M. Verdaguer-Tremolosa
    M. López-Cano
    Hernia, 2023, 27 : 207 - 207